Isis Pharmaceuticals To Review CHMP Opinion On KYNAMRO™

           Isis Pharmaceuticals To Review CHMP Opinion On KYNAMRO™

Conference Call and Webcast Scheduled for Friday, December 14 at 8:30 a.m. EST

PR Newswire

CARLSBAD, Calif., Dec. 14, 2012

CARLSBAD, Calif., Dec. 14, 2012 /PRNewswire/ --Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS) announced today that it will review the CHMP opinion on
KYNAMRO™ in a conference call and webcast on Friday, December 14, 2012 at 8:30
a.m. Eastern Time. This call will be archived for a limited time on Isis' Web
site.

CONFERENCE CALL
At 8:30 a.m. Eastern Time, Friday, December 14, 2012, Isis will conduct a live
webcast and conference call. Interested parties may listen to the call by
dialing 1-866-783-2144, or 1-857-350-1603 for international callers, and refer
to passcode "ISIS 2012." The webcast can be accessed at wwww.isispharm.com.
A webcast replay will be available for a limited time at the same address.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 25 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product,
KYNAMRO™, in the United States and Europe following regulatory approval.
Isis' patents provide strong and extensive protection for its drugs and
technology. Additional information about Isis is available at
www.isispharm.com.

ISIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis'
collaboration with Genzyme, a sanofi company, and the development, activity,
therapeutic potential and safety of KYNAMRO™ in treating patients with high
cholesterol. Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs, including the planned
commercialization of KYNAMRO, is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective for use as
human therapeutics, and in the endeavor of building a business around such
drugs. Isis' forward-looking statements also involve assumptions that, if
they never materialize or prove correct, could cause its results to differ
materially from those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on facts and
factors currently known by Isis. As a result, you are cautioned not to rely
on these forward-looking statements. These and other risks concerning Isis'
programs are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31, 2011 and its most recent quarterly report
on Form 10-Q, which are on file with the SEC. Copies of these and other
documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.
KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.

Website: http://www.isispharm.com
Contact: D. Wade Walke, Ph.D., Executive Director, Corporate Communications
and Investor Relations, +1-760-603-2741; Amy Blackley, Ph.D., Associate
Director, Corporate Communications, +1-760-603-2772
 
Press spacebar to pause and continue. Press esc to stop.